FeesSafety
Pluang+

Stoke Therapeutics eyes 2027 readout for potential first disease-modifying Dravet syndrome therapy.

Market News
19 Oct 2026, 23:34 WIB
Seeking Alpha
View Source
Bullish
Stoke Therapeutics eyes 2027 readout for potential first disease-modifying Dravet syndrome therapy.

Stoke Therapeutics is preparing for a key 2027 data readout of zorevunersen, which could become the first disease-modifying treatment for Dravet syndrome. The company has a strong financial position with $420 million in cash and a recent $65.7 million share sale, supporting operations into early 2028. The FDA's acceptance of a cognition/behavior endpoint for the EMPEROR trial lowers regulatory risks and sets zorevunersen apart from symptomatic treatments. Current market valuation suggests only a 30–40% chance of trial success, indicating potential upside for investors ahead of the 2027 catalyst.

Stoke Therapeutics' recent FDA milestone provides context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: Among 150 priced US health-sector stocks tradable on Pluang, 87 rose and 62 fell today. Notable movers include IBRX at USD 8.46 with a 1-day change of -7.84% and a Pluang order activity split of 33% Sell / 67% Buy, typical hold time 2 days; DYN at USD 15.31 up 7.44%, typical hold time 4 days; and TNGX at USD 23.60 up 7.08%, typical hold time 5 days.

More News

PBF Energy cuts net debt by $1.2B, boosts dividend 18%, and expects $130M interest savings in 2027

PBF Energy cuts net debt by $1.2B, boosts dividend 18%, and expects $130M interest savings in 2027

PBF Energy reduced its net debt by over $1.2 billion in Q3 2026, part of a broader effort that has cut more than $2 billion in net debt this year. This debt reduction is expected to lower interest expenses by $130 million in 2027, improving financial...

Company Fundamentals
Bullish
1 hour ago
Railcar scrapping outpaces production in 2026, boosting lease prices and fleet investment at Trinity Industries.

Railcar scrapping outpaces production in 2026, boosting lease prices and fleet investment at Trinity Industries.

In 2026, railcar scrapping in North America is expected to reach 40,000 units, surpassing new railcar production and tightening market supply. Trinity Industries has already met its three-year net fleet investment target ahead of schedule, highlighti...

Company Fundamentals
Bullish
1 hour ago
TMD Energy files annual report with audited financials for fiscal year ending June 2026

TMD Energy files annual report with audited financials for fiscal year ending June 2026

TMD Energy Limited has filed its annual report on Form 20-F with the SEC, including audited consolidated financial statements for the fiscal year ended June 30, 2026. The report is accessible online and hard copies are available free to shareholders ...

Company Fundamentals
Neutral
1 hour ago
Dividend Kings Abbott, McDonald's, and Tennant offer buying opportunities amid recent pullbacks and strategic moves.

Dividend Kings Abbott, McDonald's, and Tennant offer buying opportunities amid recent pullbacks and strategic moves.

Abbott Laboratories, McDonald's, and Tennant, all Dividend Kings with over 50 years of consecutive dividend increases, have recently seen their stock prices dip, presenting buying opportunities. Abbott plans to spin off its struggling nutrition divis...

Company Fundamentals
Bullish
1 hour ago
Extra Space Storage raises 2026 earnings forecast on strong revenue growth and cost cuts

Extra Space Storage raises 2026 earnings forecast on strong revenue growth and cost cuts

Extra Space Storage raised its full-year 2026 earnings guidance after reporting strong third-quarter results, including $2.17 per share in core funds from operations and 2.7% same-store revenue growth across 27 top markets. The company credited impro...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App